Navigation Links
Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
Date:7/21/2008

dy was established for all patients. All data have been checked for completeness and the data file for analysis was closed on 30 June 2008.

The scientific leadership of the study was a Steering Committee consisting of 14 academic representatives of centres in each of the participating countries and two members (a statistician and a coordinator) representing the funders. The SEAS study is funded by the pharmaceutical companies Merck Sharp & Dohme (MSD) and Schering-Plough who market the drugs being tested. All clinical endpoint events were adjudicated by an independent committee that was blinded to the study treatment allocation. The study was monitored by an independent Data Safety and Monitoring Board. Data collection was performed by MSD, and the data were analyzed by statisticians at Ulleval University Hospital in Oslo, Norway, and at MSD.

The primary endpoint of the SEAS study was "major cardiovascular events", which is the composite of events associated with aortic valve disease and with atherosclerotic disease. The secondary endpoints were the two separate components of the primary endpoint: "aortic valve disease events" (surgical valve replacement, hospitalization because of heart failure, and cardiovascular death); and "atherosclerotic disease events" (non-fatal myocardial infarction, coronary artery bypass surgery or percutaneous coronary intervention, hospitalization because of unstable angina pectoris, non-haemorrhagic stroke and cardiovascular death). Subsidiary outcomes included echocardiographic evidence of aortic stenosis progression and safety.

Compared with placebo, the combination of simvastatin and ezetimibe reduced LDL-cholesterol by an average of 61%, corresponding to a reduction of about 2 mmol/L (76 mg/dl), and this effect was sustained throughout the study. 688 patients had one or more primary endpoint events. No significant difference was observed between the treatment groups for the combined primary endpoint (333 patien
'/>"/>

SOURCE ;
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  After the February 2014 ... Injury billing solution for medical practices and management ... toward the new software. "The feedback has ... Thompson . "The sheer number of demos and new ... need was for these types of software features." ...
(Date:8/27/2014)... 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) has ... (FDA) to initiate a Phase 1/2a clinical trial of ... cord injury.  The approved trial follows the successful completion ... and is designed to assess safety and activity of ... spinal cord injuries, the first targeted indication for AST-OPC1 ...
(Date:8/26/2014)... -- Intelomed is pleased to announce that Mary ... the Vice President of Clinical Affairs. With over 30 ... industry, Kay,s experience in taking medical technology and associated ... global expansion, is a valuable addition to the Intelomed ... our team, and I am confident her focused and ...
Breaking Medicine Technology:Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2
(Date:8/27/2014)... Aug. 27, 2014 (HealthDay News) -- A new genetic ... to fight the bowel disorder, researchers report. ... that affect how their genes work, and said these ... with raising the possibility of a simple diagnostic test ... the disease develops and suggest possible gene targets for ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The ... the recipients of the 2014-2016 Basic Research Fellowships and ... career scientists, the ABTA is seeding the field with ... change our understanding of the causes, effects, diagnosis and ... by a scientific committee based on the potential to ...
(Date:8/27/2014)... According to a new market ... Market (Applications: Cardiovascular, Gynecology, Pain Management, Oncology, Urology, ... - Global Industry Analysis, Size, Share, Growth, Trends ... technologies market was valued at USD 4,698 million ... market worth USD 10,611 million in 2020 at ...
(Date:8/27/2014)... Disability (CLD) has received a two-year, $600,000 grant ... the Health Resources and Services Administration to support ... at improving services for children and youth with ... project, CLD worked with an Autism Advisory Council ... resulting plan addresses priorities of increased awareness of ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Representatives with ... added Italy to its list of destinations for International ... for Recharge Retreats, explained that the company chose Italy ... destination for yoga teacher trainings since it's an easy ... journey for people traveling from all over Europe, UK, ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 2Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 3
... ,KO Cancer, with Susan G. Komen for the Cure, ... boxers,Felix "Tito" Trinidad and Roy Jones Jr. -- who will ... Jan. 19 -- have teamed with Susan G.,Komen for the ... activists, to help educate and raise awareness regarding the,deadly disease., ...
... diagnostic imaging, BLOOMINGTON, Minn., Dec. 21 ... efficiency of care reduced,medical expenses by $74 million ... introduced in February, reduced unnecessary,tests by more than ... from the American College of Radiology to confirm ...
... BROOK, Ill. December 21, 2007 The ... for the role of endoscopy in treating dyspepsia, discomfort ... a fourth of the population in Western countries. ... instrument to evaluate the inside of the esophagus, stomach ...
... for 2007, CONCORD, Ontario, Dec. 21 ... ,OTG, ,the Company,), a,leading multi- industry computer hardware, ... received an order for 100TB SAN dedicated,to pioneering ... oncology hospitals. The EqualLogic iSCSI SAN order is ...
... HLS ) announced today that its Board of Directors ... on its 6.5%,Series A Convertible Perpetual Preferred Stock, payable ... 2, 2008., About HealthSouth, HealthSouth is the ... states across the country and in,Puerto Rico, HealthSouth serves ...
... by Dr. Steve Bailey, an internationally recognized sports historian, ... the beginnings, achievements and events that shaped the Paralympic ... Movement and other able-bodied sports. , In addition ... First establishes key players in administration and sports politics, ...
Cached Medicine News:Health News:Don King Enlists Prizefighters Felix 'Tito' Trinidad and Roy Jones Jr. to Strike a Blow against Breast Cancer 2Health News:Don King Enlists Prizefighters Felix 'Tito' Trinidad and Roy Jones Jr. to Strike a Blow against Breast Cancer 3Health News:HealthPartners Reports 2007 Most Cost Effective Programs Reduce Expenses by $74 Million 2Health News:ASGE offers guidelines on endoscopic treatment of dyspepsia 2Health News:ASGE offers guidelines on endoscopic treatment of dyspepsia 3Health News:On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects 2Health News:On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects 3Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2Health News:First reputable book on the history of the Paralympic Movement 2
The playful pattern of this lens features sky-blue forms fanning out from the center of your eye....
This design features a solid red iris....
Tempting and mesmerizing Jaguar features a narrow black slit surrounded by reflective metallic teal....
Maumenee vitreous aspirating cannula, 18 gauge....
Medicine Products: